Search Results
619 results
Your search is now limited to «Chemotherapy» expert search.
WN.com 03/20/2019 16:56
Radiomics predicts who will benefit from chemotherapy.
More from WN.com:
ecancer news 03/20/2019 11:00
Researchers use radiomics to predict which NSCLC patients will benefit from chemotherapy.
More from ecancer news:
World Pharma News 03/20/2019 07:00
Serious adverse reactions occurred in 37% of people receiving Tecentriq plus chemotherapy compared to 35% of people receiving chemotherapy alone.
More from World Pharma News:
ClinicalTrials.gov 03/19/2019 09:24
The goal of this clinical research study is to learn if one acupuncture treatment approach is more effective than another in helping to relieve chemo-therapy induced neuropathy in cancer patients.
More from ClinicalTrials.gov:
Business Wire 03/18/2019 21:15
Serious adverse reactions occurred in 37 percent of people receiving Tecentriq plus chemotherapy compared with 35 percent of people receiving chemotherapy alone.
More from Business Wire:
Annals of Internal Medicine 03/18/2019 17:45
574 patients ≥ 18 years of age (mean age 61 y, 58% women) who were starting a new course of chemotherapy with planned treatment duration ≥ 3 months for newly diagnosed cancer or cancer that had progressed after complete or partial remission, and who had intermediate-to-high risk for VTE (Khorana score ≥ 2 out of 6.
Targeted Oncology 03/18/2019 16:18
... RECOVER 3 trials, which showed that eflapegrastim was noninferior to pegfilgrastim (Neulasta), in terms of absolute risk reduction of severe neutropenia, in patients with early-stage breast cancer who experienced neutropenia due to myelosuppressive cytotoxic chemotherapy.
More from Targeted Oncology:
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
More from Nature - Cell Biology:
Bromodomain and extraterminal domain (BET) family proteins such as BRD4 are epigenetic readers that control expression of a number of oncogenic proteins. Targeting this family of proteins has recently emerged as a promising anticancer approach. BET inhibitors (BETi), either alone or in combination with other anticancer agents, have exhibited efficacy in a variety of tumors. However, the molecular mechanisms underlying differential response to BETi are not well understood. In this study, we report that death receptor 5 (DR5), a key component of the extrinsic apoptotic pathway, is markedly induced in response to BRD4 depletion and BETi treatment in colorectal cancer cells. Induction of DR5, following BET inhibition, was mediated by endoplasmi.
More from Cancer Research - Recent Issues (abstracts):
Purpose:. Although myeloablative HLA haploidentical hematopoietic stem cell transplantation (haplo-HSCT) following pretransplant anti-thymocyte globulin (ATG) and granulocyte colony-stimulating factor (G-CSF) stimulated grafts (ATG+G-CSF) has been confirmed as an alternative to HSCT from HLA-matched sibling donors (MSD), the effect of haplo-HSCT on postremission treatment of patients with acute myeloid leukemia (AML) with intermediate risk (int-risk AML) who achieved first complete remission (CR1) has not been defined. Patients and Methods:. In this prospective trial, among 443 consecutive patients ages 16–60 years with newly diagnosed de no vo AML with int-risk cytogenetics, 147 patients with molecular int-risk AML who achieved CR1 within tw.
More from Clinical Cancer Research - Recent Issues (abstracts):
FeedNavigator 03/13/2019 14:47
Objective of the study was to investigate the impact of metformin exposure during adjuvant chemotherapy on overall survival (OS) and relapse‐free survival (RFS.
More from FeedNavigator:
ENDPOINTS 03/13/2019 09:55
Days after Celgene’s Abraxane secured approval in combination with Roche’s checkpoint inhibitor for frontline use in triple negative breast cancer, the US drugmaker reported that the chemotherapy failed to improve progression-free survival in a pivotal study involving pancreatic cancer patients who had undergone surgical resection.
More from ENDPOINTS:
CT was discontinued if toxicities did not resolve by day 21 of a cycle or if there was a delay in chemotherapy greater than 16 weeks.
More from American Society of Clinical Oncolgy (ASCO):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications